BRAF – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of BRAF comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of BRAF for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.
Clarivate Epidemiology’s BRAF forecast will answer the following questions:
- Of all people with BRAF, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with BRAF, how many in each of the major mature pharmaceutical markets are drug-treatable?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of BRAF over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts patient populations, as follows:
- Incident cases of BRAF-mutated tumors by primary tumor site.
- Incident cases of BRAF-mutated tumors by metastatic status.
- First-line drug-treatable population of BRAF-mutated tumors, split by site of primary tumor.
Note: Coverage may vary by country.
Table of contents
- BRAF - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of BRAF
- Diagnosed incident cases of BRAF-mutated cancer
- Diagnosed incident cases of BRAF-mutated melanoma
- Diagnosed incident cases of BRAF-mutated papillary thyroid cancer
- Diagnosed incident cases of BRAF-mutated anaplastic thyroid cancer
- Diagnosed incident cases of BRAF-mutated colorectal cancer
- Diagnosed incident cases of BRAF-mutated NSCLC
- Diagnosed incident cases of recurrent BRAF-mutated cancer
- Diagnosed drug-treatable first-line BRAF-mutated population
- Risk / protective factors applied to disease forecast models
- Reference Materials
Mohani Latwal, B.P.T., M.P.H., Epidemiologist, Epidemiology. Prior to joining Clarivate, she worked as a deputy manager at an NGO. She received her bachelor’s degree in physiotherapy from Delhi University and her master’s degree in public health with a specialization in social epidemiology from the Tata Institute of Social Sciences in Mumbai.
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. A former microbiologist, he was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and earned a postgraduate degree in public health specializing in epidemiology from Manipal University. He specializes in real-world data analysis, cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer.